Boehringer strikes $7 billion cancer deal with Sino Biopharmaceutical

Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near term for options on six preclinical cancer programs, with milestone payments that could reach $7 billion plus royalties.

Why it matters: The deal is one of the largest licensing packages yet for Chinese-originated antibody-drug conjugate and T-cell engager programs, and it deepens a German buyer’s reliance on China for early oncology pipelines.

Data as of Joint Boehringer Ingelheim and Sino Biopharmaceutical announcement of November 4, 2026, and Reuters reporting of the same day, both read in full. The $7 billion figure is potential milestone payments only and is not guaranteed; all six programs are preclinical. Developing item.

Boehringer Ingelheim and Sino Biopharmaceutical announced a multi-program option and licence agreement on Wednesday covering six preclinical cancer programs built on antibody-drug conjugate and T-cell engager technologies, five of them from Sino’s LaNova Medicines subsidiary in Shanghai and one from Beijing Tide Pharmaceutical. Sino will receive $358 million in upfront and near-term payments and could receive a further $7 billion in option-exercise, development, regulatory and commercial milestone payments, plus tiered royalties of up to double digits on future sales.

Sino will lead early development of the programs through global Phase I trials. Once agreed clinical milestones are reached, Boehringer may take exclusive development, manufacturing and commercialisation rights to four programs outside mainland China, Hong Kong and Macau, and to the remaining two programs worldwide.

Boehringer strikes $7 billion cancer deal with Sino Biopharmaceutical

Sources